✨ Free AI Report
LivaNova PLC: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research LivaNova PLC
Company Research

LivaNova PLC: Business Overview, Financials & Competitive Analysis

LivaNova advances patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies. The company delivered double-digit revenue growth in 2025 with full-ye...

Analyst-debate audio for LivaNova PLC

AskCyborg analysts argue the bull and bear cases for LivaNova PLC across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Solid

Cyborg Score thesis

Growth drivers include ongoing strength in cardiopulmonary and epilepsy businesses, new product launches, entry into the...

Read the full analyst-debate transcript →
Industry Medical Devices - Cardiac Surgery & Neuromodulation
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest LivaNova PLC Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

LivaNova PLC Overview

Pro stress-test →

LivaNova advances patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies. The company delivered double-digit revenue growth in 2025 with full-year revenue of $1.39 billion, increasing 10.7% on an organic basis. With operations in over 100 countries and strategic expansion into emerging markets like obstructive sleep apnea, the company is positioned as a market leader in critical care and neuromodulation.

Strategic Profile

Pro stress-test →

LivaNova is pursuing strategic growth in high-growth segments such as obstructive sleep apnea and digital health for neuromodulation, while maintaining durable market share and profit gains in core Cardiopulmonary and Epilepsy businesses. The company is investing in advanced R&D, digital capabilities with FDA-approved platforms, and scaling next-generation manufacturing while deleveraging its balance sheet.

Competitive Landscape

Pro stress-test →

Increased competition risks are noted in the field, with valuation compression expected as growth moderates. Main competitive risks include supply chain constraints and slow penetration rates in new markets. LivaNova competes in cardiac surgery devices and neuromodulation therapy against larger diversified medical device companies.

Industry Context

LivaNova PLC operates in Medical Devices - Cardiac Surgery & Neuromodulation.

Key facts

Founded: 2015 · Headquarters: London, United Kingdom · Employees: 3,300 · Revenue: $1.39B · Market cap: $3.84B

What the analysts stress-tested

The top findings that survived the multi-agent debate for LivaNova PLC.

  • CMS increased reimbursement for VNS Therapy for Drug-Resistant Epilepsy effective January 1, 2026, significantly reducing a known barrier to procedure penetration.
  • FDA approved LivaNova's cloud-based digital health platform for epilepsy, establishing the foundation for a Connected Care roadmap with initial clinician portal rollout.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Feb 2026Q4 2025 earnings show 9.5% organic growth; issued 6-7% 2026 revenue guidance
  • Jan 2026Completed full repayment of remaining term facilities; RECOVER durability study published showing 80% maintained benefit through 24 months
  • +2 moreTrack every material event for LivaNova PLC as it happens. Explore monitoring →
Get alerted when LivaNova PLC has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Cardiopulmonary Bypass DevicesDiversified medical device leader with cardiac surgery portfolio→Neuromodulation TherapiesOffers competing neuromodulation solutions→Cardiac Support SystemsCardiovascular device manufacturer→

Compare LivaNova PLC with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

LivaNova PLC operates in Medical Devices - Cardiac Surgery & Neuromodulation. See how the rest of the sector scores on the Cyborg framework.

Browse Medical Devices - Cardiac Surgery & Neuromodulation research →
NEW · MCP server

Ask your AI assistant about LivaNova PLC

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare LivaNova PLC and its top competitor on Cyborg Score”
“What did LivaNova PLC do this quarter?”
“Is LivaNova PLC a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does LivaNova PLC do?+
LivaNova advances patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies. The company delivered double-digit revenue growth in 2025 with full-ye...
What is LivaNova PLC's Cyborg Score?+
LivaNova PLC has a Cyborg Score of 7/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are LivaNova PLC's main competitors?+
Named competitors include Cardiopulmonary Bypass Devices, Neuromodulation Therapies, Cardiac Support Systems. The full competitive landscape is in the AskCyborg report.
How can I get the full LivaNova PLC research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the LivaNova PLC research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track LivaNova PLC over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Medical Devices - Cardiac Surgery & Neuromodulation research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7LivaNova PLC